ABBV vs GILD
AbbVie (ABBV) and Gilead Sciences (GILD) compared side by side. AbbVie (ABBV) is larger, with a market cap of $504.8B versus $193.5B for Gilead Sciences, about 2.6 times the size. GILD returned +32.4% over the past year including dividends, versus +28.9% for ABBV, through October 23, 2026..
Head to head
| Metric | ABBV | GILD |
|---|---|---|
| Market cap | $504.8B | $193.5B |
| P/E (TTM) | 80.7x | — |
| Forward P/E | 17.6x | 15.6x |
| Revenue (TTM) | $64.4B | $30.5B |
| Revenue growth | 10.2% | 10.2% |
| Gross margin | 72.8% | 79.6% |
| Operating margin | 40.0% | 33.7% |
| Free cash flow | $18.2B | $12.9B |
| Dividend yield | 2.42% | 2.10% |
| 1-year return | +28.9% | +32.4% |
| 5-year return (annual) | +25.6% | +22.6% |
| Max drawdown | -45% | -71% |
| FI Handbook grade | B | B- |
Highlighted: the stronger figure on metrics where higher or lower is clearly better.
Growth of $10,000 (5 years, price only)
$10.0K
$20.0K
20222023202420252026
ABBV vs GILD FAQ
Which is bigger, ABBV or GILD?
AbbVie (ABBV) is larger, with a market cap of $504.8B versus $193.5B for Gilead Sciences, about 2.6 times the size.
Which stock performed better over the past year, ABBV or GILD?
GILD returned +32.4% over the past year including dividends, versus +28.9% for ABBV, through October 23, 2026.
Which pays a higher dividend, ABBV or GILD?
ABBV yields 2.42% versus 2.10% for GILD.
Full pages: AbbVie · Gilead Sciences